Cytek Biosciences (CTKB) Current Deferred Revenue (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Current Deferred Revenue data on file, last reported at $30.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 8.4% year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $30.0 million (up 8.4% YoY), and the FY2025 full-year result was $28.5 million, up 11.82% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $30.0 million, up from $28.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $30.0 million in Q1 2026 and bottomed at $10.0 million in Q2 2022.
• The 5-year median for Current Deferred Revenue is $23.5 million (2022), against an average of $22.6 million.
• Peak annual rise in Current Deferred Revenue reached 114.03% in 2022, while the deepest fall reached 48.37% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $13.0 million in 2022, then jumped by 74.77% to $22.7 million in 2023, then climbed by 12.32% to $25.5 million in 2024, then gained by 11.82% to $28.5 million in 2025, then rose by 5.36% to $30.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $30.0 million (Q1 2026), $28.5 million (Q4 2025), and $28.7 million (Q3 2025), per Business Quant data.

Peer Comparison